Format

Send to:

Choose Destination
See comment in PubMed Commons below
World J Gastroenterol. 2010 Mar 14;16(10):1171-6.

Steatosis as a co-factor in chronic liver diseases.

Author information

  • 1Department of Biochemistry and Medical Biochemistry, University Federico II, Via Comunale margherita 482, 80145 Naples, Italy.

Abstract

The finding of lipid accumulation in the liver, so-called hepatic steatosis or non-alcoholic fatty liver disease, is a common condition frequently found in healthy subjects. Its prevalence, in fact, has been estimated by magnetic resonance studies to be about 35% in the general population and 75% in obese persons. Nevertheless, its presence generates liver damage only in a small percentage of subjects not affected by other liver diseases. It should be defined as a "co-factor" capable of affecting severity and progression, and also therapeutic perspectives, of liver diseases to which it is associated. Herein we will evaluate the impact of hepatic steatosis and obesity on the most common liver diseases: chronic viral hepatitis C and B, and alcoholic liver disease.

PMID:
20222159
[PubMed - indexed for MEDLINE]
PMCID:
PMC2839168
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Baishideng Publishing Group Inc. Icon for PubMed Central
    Loading ...
    Write to the Help Desk